

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CYBIN IRL LIMITED Confirmation No.: 7822
Serial No.: 18/688,125 Group No.:
Filing or 371(c) Date: March 31, 2022 Examiner:
Entitled: COMBINATION DRUG THERAPIES

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application.

1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)
2. Int'l Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 18/688125 Pending Claims	References
--------------------------------------	------------

<p>30. A pharmaceutical composition, comprising; a 5-HT2A receptor agonist; nitrous oxide; and a pharmaceutically acceptable excipient.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In another aspect the invention provides a pharmaceutical composition comprising a RAAD and a mTOR inhibitor and/or immune suppressant...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Background of the Invention: Non-limiting examples of NMDA receptor modulators are...nitrous oxide... NMDA receptor modulators are part of a new class of rapid-acting antidepressants (RAAD...</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p>
<p>31. The pharmaceutical composition of claim 30, which is formulated for administration via inhalation.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In another aspect the invention provides a pharmaceutical composition comprising a RAAD and a mTOR inhibitor and/or immune suppressant...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Background of the Invention: Non-limiting examples of NMDA receptor modulators are...nitrous oxide... NMDA receptor modulators are part of a new class of rapid-acting antidepressants (RAAD...</p>

	<p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof using any known and applicable route of administration, such as for example, (intra)nasal, inhalational...</p>
<p>32. A method of treating a subject with a central nervous system (CNS) disorder or a psychiatric disease, the method comprising: administering to the subject a therapeutically effective amount of a 5-HT_{2A} receptor agonist and a N-methyl-D-aspartate (NMDA) receptor antagonist.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Background of the Invention: Non-limiting examples of NMDA receptor modulators are...ketamine...NMDA receptor modulators are part of a new class of rapid-acting antidepressants (RAAD...</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p>

	<p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p>
<p>33. The method of claim 32, wherein the CNS disorder or a psychiatric disease is at least one selected from the group consisting of post-traumatic stress disorder (PTSD), major depressive disorder (MDD), treatment-resistant depression (TRD), suicidal ideation, suicidal behavior, major depressive disorder with suicidal ideation or suicidal behavior, melancholic depression, atypical depression, dysthymia, non-suicidal self-injury disorder (NSSID), bipolar and related disorders, obsessive-compulsive disorder (OCD),</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p>

<p>compulsive behavior and other related symptoms, generalized anxiety disorder (GAD), acute psychedelic crisis, social anxiety disorder, alcohol use disorder, opioid use disorder, amphetamine use disorder, nicotine use disorder, cocaine use disorder, Alzheimer's disease, cluster headache and migraine, attention deficit hyperactivity disorder (ADHD), pain and neuropathic pain, aphantasia, childhood-onset fluency disorder, major neurocognitive disorder, mild neurocognitive disorder, chronic fatigue syndrome, Lyme disease, gambling disorder, anorexia nervosa, bulimia nervosa, binge-eating disorder, pedophilic disorder, exhibitionistic disorder, voyeuristic disorder, fetishistic disorder, sexual masochism or sadism disorder, transvestic disorder, sexual dysfunction, peripheral neuropathy, and obesity.</p>	<p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p> <p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p> <p>From Detailed Description: In one embodiment, an anxiety disorder comprises acute stress disorder, anxiety due to a medical condition, generalized anxiety disorder, panic disorder, panic attack, a phobia, post-traumatic stress disorder, separation anxiety disorder, social anxiety disorder, substance-induced anxiety disorder, or selective mutism.</p> <p>From Detailed Description: In one embodiment, a depressive disorder is chosen from atypical depression, bipolar disorder, catatonic depression, depressive disorder due to a medical condition, major depressive disorder, postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder.</p>
<p>34. The method of claim 32, wherein the CNS disorder or a psychiatric disease is major depressive disorder (MDD).</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-</i></p>

	<p><i>limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: In one embodiment, a depressive disorder is chosen from atypical depression, bipolar disorder, catatonic depression, depressive disorder due to a medical condition, major depressive disorder, postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder.</p>
<p>36. The method of claim 32, wherein the CNS disorder or a psychiatric disease is generalized anxiety disorder (GAD).</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more</p>


	<p>psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term “serotonergic drug” refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: In one embodiment, an anxiety disorder comprises acute stress disorder, anxiety due to a medical condition, generalized anxiety disorder, panic disorder, panic attack, a phobia, post-traumatic stress disorder, separation anxiety disorder, social anxiety disorder, substance-induced anxiety disorder, or selective mutism.</p>
<p>37. The method of claim 32, wherein the CNS disorder or a psychiatric disease is social anxiety disorder.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a “NMDA receptor antagonist” refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int’l Pat. App. Pub. No. WO/2019/099745 “COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID” (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term “serotonergic drug” refers to a compound that binds to, blocks, or otherwise influences (e.g.,</p>

	<p>via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: In one embodiment, an anxiety disorder comprises acute stress disorder, anxiety due to a medical condition, generalized anxiety disorder, panic disorder, panic attack, a phobia, post-traumatic stress disorder, separation anxiety disorder, social anxiety disorder, substance-induced anxiety disorder, or selective mutism.</p>
<p>38. The method of claim 32, wherein the CNS disorder or a psychiatric disease is obsessive-compulsive disorder (OCD).</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of</p>

	<p>intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p> <p>From Detailed Description: In one embodiment, a compulsive disorder is chosen from addiction, body dysmorphic disorder, excoriation disorder, hoarding disorder, obsessive-compulsive disorder, and trichotillomania.</p>
<p>39. The method of claim 32, wherein the CNS disorder or a psychiatric disease is alcohol use disorder.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a “NMDA receptor antagonist” refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int’l Pat. App. Pub. No. WO/2019/099745 “COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID” (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term “serotonergic drug” refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p> <p>From Detailed Description: Disclosed herein is a method of treating alcohol addiction, comprising identifying a person in need of treatment and administering a composition disclosed herein to the person in need of treatment.</p>

40. The method of claim 32, wherein the 5-HT_{2A} receptor agonist is a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof wherein: X₁ and X₂ are independently selected from the group consisting of hydrogen, deuterium, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl; Y₁ and Y₂ are independently selected from the group consisting of hydrogen and deuterium; R₂ is selected from the group consisting of hydrogen, deuterium, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or

From the application of interest 18/688125 Claim 40: The method of claim 32, wherein the 5-HT_{2A} receptor agonist is a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof



wherein:

X₁ and X₂ are independently selected from the group consisting of hydrogen, deuterium, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl;

Y₁ and Y₂ are independently selected from the group consisting of hydrogen and deuterium;

R₂ is selected from the group consisting of hydrogen, deuterium, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl;

R₄ and R₅ are independently selected from the group consisting of hydrogen, deuterium, hydroxyl, and unsubstituted or substituted alkoxy;

R₆ and R₇ are independently selected from the group consisting of hydrogen, deuterium, and halogen; and

R₉ and R₁₀ are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl.

From the application of interest 18/688125 [0447]: As used herein, a “NMDA receptor antagonist” refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...

2. Int’l Pat. App. Pub. No. WO/2019/099745 “COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID” (Published May 23, 2019)

From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof.

<p>substituted aryl, and unsubstituted or substituted heteroaryl; R4 and R5 are independently selected from the group consisting of hydrogen, deuterium, hydroxyl, and unsubstituted or substituted alkoxy; R6 and R7 are independently selected from the group consisting of hydrogen, deuterium, and halogen; and R9 and R10 are independently selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl.</p>	<p>In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term “serotonergic drug” refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...psilocin...5-MeO-DMT...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p>
<p>41. The method of claim 32, wherein the 5-HT2A receptor agonist and the NMDA receptor antagonist are administered 1 to 8 times over a treatment course.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a “NMDA receptor antagonist” refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>1. Int’l Pat. App. Pub. No. WO/2020/041329 “COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES” (Published February 27, 2020)</p>

	<p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include: ketamine</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Methods: In certain embodiments, the compositions of the invention are administered to the patient in dosages that range from one to five times per day or more. In another embodiment, the compositions of the invention are administered to the patient in range of dosages that include, but are not limited to, once every day, every two, days, every three days to once a week, and once every two weeks.</p>
<p>42. The method of claim 32, wherein the 5-HT2A receptor agonist and the NMDA receptor antagonist are administered concurrently as a single pharmaceutical composition.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a “NMDA receptor antagonist” refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int’l Pat. App. Pub. No. WO/2019/099745 “COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID” (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a</p>

	<p>composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term “serotonergic drug” refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise administering one or more active ingredients, e.g., psilocybin derivatives, cannabinoids, terpenes, neurotransmitter activity modulators, etc., in a single dosage, e.g., a single tablet, a single composition, a single formulation, etc.</p>
<p>43. The method of claim 32, wherein the 5-HT_{2A} receptor agonist and the NMDA receptor antagonist are administered as an aerosol to the subject by inhalation.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a “NMDA receptor antagonist” refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>1. Int’l Pat. App. Pub. No. WO/2020/041329 “COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES” (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include: ketamine</p>

	<p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Methods: Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation</p>
<p>44. The method of claim 43, wherein the aerosol is in the form of a mist.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include: ketamine</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated</p>

	<p>in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Methods: Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation</p>
<p>48. The method of claim 43, wherein the NMDA receptor antagonist is nitrous oxide.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Methods: Non-limiting examples of NMD A receptor modulators are...nitrous oxide...</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Methods: Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation</p>
<p>49. The method of claim 48, wherein the</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine</i></p>

<p>aerosol comprises the nitrous oxide in a gas phase of the aerosol.</p>	<p><i>derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Methods: Non-limiting examples of NMD A receptor modulators are...nitrous oxide...</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Methods: Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation</p>
<p>61. The method of claim 32, wherein the NMDA receptor antagonist is nitrous oxide or ketamine or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p>2. Int'l Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof.</p>

	<p>In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p>
<p>65. The method of claim 32, wherein the 5-HT_{2A} receptor agonist and the NMDA receptor antagonist are administered sequentially as separate pharmaceutical compositions.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT_{2A} receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p>

	<p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise administering one or more active ingredients, e.g., psilocybin derivatives, cannabinoids, terpenes, neurotransmitter activity modulators, etc., in more than two doses, e.g., two or more tablets, two or more compositions, two or more formulations, etc.</p>
<p>66. The method of claim 32, wherein the 5-HT2A receptor agonist and the NMDA receptor antagonist are administered concurrently as separate pharmaceutical compositions.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...DMT...</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p>

	<p>From Detailed Description: In one embodiment, the methods disclosed herein comprise administering one or more active ingredients, e.g., psilocybin derivatives, cannabinoids, terpenes, neurotransmitter activity modulators, etc., in more than two doses, e.g., two or more tablets, two or more compositions, two or more formulations, etc.</p>
<p>67. The method of claim 32, wherein the 5-HT2A receptor agonist is administered intravenously and the NMDA receptor antagonist is administered via inhalation.</p>	<p><i>From the application of interest 18/688125 [0229]: In preferred embodiments, the 5-HT2A receptor agonist is at least one tryptamine derivative selected from the group consisting of...N,N-dimethyltryptamine (DMT)</i></p> <p>1. Int'l Pat. App. Pub. No. WO/2020/041329 "COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES" (Published February 27, 2020)</p> <p>From Brief Summary of the Invention: In one aspect, the invention provides a method of treating or preventing a mood disorder in a human subject, wherein the disease or disorder is treatable or preventable by administering a rapid-acting antidepressant (RAAD) to the subject, the method comprising administering to the subject a therapeutically effective amount of the RAAD...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...DMT...</p> <p>From Methods: Non-limiting examples of RAADs useful within the methods of the invention include:...ketamine...</p> <p>From Administration/Dosage/Formulations: In one embodiment, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients...</p> <p>From Compositions: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof...</p> <p>From Methods: In certain embodiments, the pharmaceutical compositions of the invention, or any of the active agents contemplated in the invention (separately and/or in combination), are administered to the subject in need thereof using any known and applicable route of administration, such as for example, (intra)nasal, inhalational, topical, oral, buccal, rectal, pleural, peritoneal, vaginal, intramuscular, subcutaneous, transdermal, epidural, intratracheal, otic, intraocular, intrathecal, and intravenous.</p>
<p>78. The method of claim 32, wherein the 5-HT2A receptor</p>	<p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-</i></p>

<p>agonist is N,N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or solvate thereof.</p>	<p><i>limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.</p> <p>From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...DMT...</p> <p>From Detailed Description: As used herein, the term "serotonergic drug" refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.</p> <p>From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...</p> <p>From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.</p>
<p>79. The method of claim 32, wherein the 5-HT2A receptor agonist is 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt or solvate thereof.</p>	<p><i>From the application of interest 18/688125 [0447]: As used herein, a "NMDA receptor antagonist" refers to a compound that decreases or inhibits the action of an N-methyl-D-aspartate (NMDA) receptor. Non-limiting examples of NMDA receptor antagonists suitable for use in the present disclosure include, but are not limited to, ketamine...</i></p> <p>2. Int't Pat. App. Pub. No. WO/2019/099745 "COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID" (Published May 23, 2019)</p> <p>From Detailed Description: In one embodiment, the methods disclosed herein comprise treating a psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein, e.g., a composition with one or more psilocybin derivatives, a composition with one or more cannabinoids, a composition with one or more terpenes, and/or a combination thereof. In one embodiment, the methods disclosed herein comprise treating a</p>

psychological disorder, e.g., an anxiety disorder, a compulsive disorder, a depressive disorder, etc., with the compositions disclosed herein and a neurotransmitter activity modulator, e.g., a serotonergic drug, a dopaminergic drug, etc.

From Detailed Description: As used herein, the term “serotonergic drug” refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor... In one embodiment, a serotonergic drug is an agonist.

From Detailed Description: Some exemplary serotonergic drugs include the following molecules:...5-MeO-DMT...

From Detailed Description: In one embodiment, a dopaminergic drug is chosen from...ketamine...

From Detailed Description: The compositions disclosed herein are useful for the treatment of compulsive disorders in humans, a variety of intractable psychiatric disorders, chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.



P.O. Box 1450
 Alexandria, VA 22313 - 1450
 www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/688,125	03/11/2025 02:38:50 PM Z ET	

Title of Invention

Application Information

APPLICATION TYPE	PATENT #
CONFIRMATION #	FILED BY Jeremy Rolquin
PATENT CENTER # 69532339	FILING DATE 02/29/2024
CUSTOMER # -	FIRST NAMED INVENTOR
INTL. APPLICATION # -	INTL. FILING DATE -
CORRESPONDENCE ADDRESS -	AUTHORIZED BY -

Documents

TOTAL DOCUMENTS: 7

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf	2	Third-Party Submission Under 37 CFR 1.290	46 KB
Third-party-notification-request.pdf	1	Request for Notification of Non-compliant Third-Party Submission	13 KB
Concise-description-generated.pdf	2	Concise Description of Relevance	25 KB
3PS-7.pdf	21	-	454 KB
3PS-7-3P.RELEVANCE.pdf (1-21)	21	Concise Description of Relevance	394 KB
3PS-7-3P.RELEVANCE.pdf (1-21)	21	Concise Description of Relevance	394 KB

1_WO2020041329.pdf		42	-	2323 KB
1_WO2020041329- FOR.pdf	(1-42)	42	Foreign Reference	2323 KB
2_WO2019099745A1.pdf		74	-	4322 KB
2_WO2019099745A1- FOR.pdf	(1-74)	74	Foreign Reference	4308 KB

Digest

DOCUMENT

MESSAGE DIGEST(SHA-512)

third-party-preissuance- submission.pdf	5591197DC162C6A2530FD4179B4765875D75CB4FA9E44DA33 F556C8BEA6B89F2363FAA9958AB9DCE9826BA7046FE6F0D6 68FC0008B1E9E8645DA10953E02DE57
Third-party-notification- request.pdf	013B9194598C355C78E6361D524858956D7440231923B1B2C1 B1544965785703F889707F7F46B019F13873F6C31815D546BB AED4A55CF2BC497E07051BC8F919
Concise-description- generated.pdf	C005ECA49277100C07D04C061E0F629D439A45119E044A61A CEEA2C9C1F0299437F3FEB0BBBA98DF21D03C201A546A7C1 994C9E2EBF019FB18DA749475054E9B
3PS-7.pdf	EC519B2EDC67E14EFDC9A09CA9A578E78643DBAE3D6E59C 30301214B32D67837C7926F6B8BA68185C2CE326B8F4D75837 1D8F91D8C7639AE1F13A650DF6CF2F9
3PS-7-3P.RELEVANCE.pdf	F7D346684B1C2A183080078A1E9B3EFE3D8A9584F669CCB76 54430E7B9D27E7010850D5A76D31FECB274059181B888D33A 0D9D13478D35E9BC417195E5E2037E
3PS-7-3P.RELEVANCE.pdf	E80083B5C03CB3790B936E4F6153CD6443A93FE77BDA986B9 F3E724CE64F91CB2D538D8E4B4894FCA8620514AB03DD75E B21B2F2F3629CEE25C212D605FF86DB
1_WO2020041329.pdf	7BC0767CCBFD48E0885CC65E494BE3E6A28BCFF23A8A71B3 27890BDE4359B49819AFE1F2BAB94496E6B7738235F8BCF1D 093BB26BBB954CF40AA182D2718A8CB
1_WO2020041329-FOR.pdf	F3E11341264250985A7980758CF3188E5CE91A5EBFF6B182D E1D8DA8144BD9B024F1EE2C986F7880A0DEE52C9628319AC 4AA5C4349EEDA44ED781F54524B9FB8
2_WO2019099745A1.pdf	A8F4DCA9DF34217127032EEAC31D24D620E4EB9630134CE0 5187500AF0DEC7B2757D1FA15F298C368682000134D0AF3BE 512D11A03C4EF2644543FB8193DAF32
2_WO2019099745A1-FOR.pdf	AB68F27C5D117900D238DADFDF84BE6AEDC28775B7C87CE C426133D6F6F98BA76954507C749A708515160C35BC9DEAA0

B05F61385666C6B0B775CB739A0A9612

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.